Clinical Trials
48 trialsNCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT01093196 2024-11-07
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT01091831 2024-11-06
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT00551928 2024-07-22
MPRvsMEL200
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT03217812 2024-04-25
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
Phase 3 Completed
NCT02678572 2023-12-21
FOCUS
Delcath Systems Inc.
Phase 3 Completed
NCT01063179 2023-06-29
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
Phase 3 Completed
NCT02063022 2022-09-19
EW-1
Italian Sarcoma Group
Phase 3 Completed
NCT02197221 2022-05-23
IFM2014-02
University Hospital, Toulouse
Phase 3 Completed
NCT00567567 2022-04-28
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT01413178 2020-04-21
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00002678 2020-04-02
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00137995 2019-08-28
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
Lymphoma Study Association
Phase 3 Completed
NCT01818752 2019-08-26
CLARION
Amgen
Phase 3 Completed
NCT00002835 2018-11-15
Combination Chemotherapy in Treating Patients With Lymphoma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00083915 2017-11-20
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
University of Arkansas
Phase 3 Completed
NCT01916252 2017-09-27
GEM2012MENOS65
PETHEMA Foundation
Phase 3 Completed
NCT01277016 2017-03-10
EMN-03
European Myeloma Network B.V.
Phase 3 Completed
NCT00477971 2016-05-17
Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Mayo Clinic
Phase 3 Completed
NCT00083551 2015-11-23
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
University of Arkansas
Phase 3 Completed
NCT00217438 2015-08-21
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT00002548 2015-03-06
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
SWOG Cancer Research Network
Phase 3 Completed
NCT02288741 2014-11-11
DSMM-II
WiSP Wissenschaftlicher Service Pharma GmbH
Phase 3 Completed
NCT00507416 2014-05-01
UPFRONT
Millennium Pharmaceuticals, Inc.
Phase 3 Completed
NCT00002802 2013-12-19
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT01998503 2013-11-29
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Nanjing University School of Medicine
Phase 3 Completed
NCT00205764 2013-11-25
Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy
Austrian Forum Against Cancer
Phase 3 Completed
NCT00004921 2013-09-17
High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005589 2013-09-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00012051 2013-08-12
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00365755 2013-08-02
Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003789 2013-07-16
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
National Cancer Institute (NCI)
Phase 3 Completed
NCT00002556 2013-05-31
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004188 2013-05-17
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
Children's Oncology Group
Phase 3 Completed
NCT00004165 2012-06-06
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Northwestern University
Phase 3 Completed
NCT00003215 2012-05-15
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
Swiss Cancer Institute
Phase 3 Completed
NCT00002945 2012-04-13
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 3 Completed
NCT00020501 2012-03-08
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00186966 2011-04-06
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
Dutch Childhood Oncology Group
Phase 3 Completed
NCT00008229 2010-09-21
Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT00003972 2010-04-02
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT01070862 2010-02-18
MAG 2002
University Hospital, Caen
Phase 3 Completed
NCT00001296 2008-03-04
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00344526 2007-06-28
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
University Hospital, Limoges
Phase 3 Completed